Most significant clincal trials of 2024
From gene therapies to psychedelics and cancer vaccines to HIV pre-exposure prophylaxis (PrEP) drugs, 2024 has been a busy year…
All articles by Abigail Beaney
Abigail Beaney
Abigail Beaney is a healthcare reporter for the Clinical Trials Arena. Coming from a journalistic background Abigail holds a BA (Hons) in Journalism from the University of Central Lancashire. Based in Manchester, Abigail has previously worked in local news and has interests in research into the treatment and prevention of cancer, heart disease and dementia.
-
-
Vertex’s stock hurt after non-opioid pain drug shows benefit similar to placebo
Vertex Pharmaceuticals’s non-opioid-based pain therapy has shown benefit in a Phase II trial in patients with painful lumbosacral radiculopathy (LSR)…
-
WHO trial guidance goes beyond race and gender when tackling diversity
Diversity has been a huge buzzword in the clinical trial space in the past few years. There has been a…
-
Novocure seeks approval after pancreatic cancer wearable scores at Phase III
Novocure is seeking regulatory approval in the US, EU, Japan and other key markets after the Phase III PANOVA-3 pancreatic…
-
Radiopharmaceutical trials face extra complexities due to nuclear red tape
The field of radiopharmaceuticals is growing rapidly, with a real buzz in oncology around emerging therapies. Radiopharmaceuticals are drugs that…
-
Cassava Sciences stock plummets after Phase III Alzheimer’s fail
Cassava Sciences’ stock has dropped by more than 80% after the company revealed its lead and only investigational product simufilam…
-
Sponsors and CROs: getting the right balance is vital
Sponsors rely on contract research organisations (CROs) to ensure a trial runs smoothly at all stages, through planning, execution, and…
-
Prostate cancer: Three drug trials to watch
Today (19 November) marks International Men’s Day with the theme for 2024 being Men's Health Champions, shining a light on…
-
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit
AC Immune’s stock price has jumped by more than 20% after all patients in a trial of its Parkinson’s disease…
-
Kezar struck again with second FDA hold
Kezar Life Sciences has been handed a second clinical hold by the US Food and Drug Administration (FDA) in as…